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Sphingosine 1-phosphate (S1P) is a lipid agonist that
regulates smooth muscle cell (SMC) and endothelial cell
functions by activating several members of the S1P sub-
family of G-protein-coupled Edg receptors. We have
shown previously that SMC differentiation is regulated
by RhoA-dependent activation of serum response factor
(SRF). Because S1P is a strong activator of RhoA, we
hypothesized that S1P would stimulate SMC differenti-
ation. Treatment of primary rat aortic SMC cells with
S1P activated RhoA as measured by precipitation with a
glutathione S-transferase-rhotekin fusion protein. In
SMC and 10T1⁄2 cells, S1P treatment up-regulated the
activities of several transiently transfected SMC-spe-
cific promoters, and these effects were inhibited by the
Rho-kinase inhibitor, Y-27632. S1P also increased
smooth muscle -actin protein levels in SMC but had no
effect on SRF binding to the smooth muscle -actin
CArG B element. Quantitative reverse transcriptase-
PCR showed that S1P treatment of SMC or 10T1⁄2 cells
did not increase the mRNA level of either of the re-
cently identified SRF co-factors, myocardin or myocar-
din-related transcription factor-A (MRTF-A). MRTF-A
protein was expressed highly in SMC and 10T1⁄2 cul-
tures, and importantly the effects of S1P were inhib-
ited by a dominant negative form of MRTF-A indicat-
ing that S1P may regulate the transcriptional activity
of MRTF-A. Indeed, S1P treatment increased the nu-
clear localization of FLAG-MRTF-A, and the effect of
MRTF-A overexpression on smooth muscle -actin pro-
moter activity was inhibited by dominant negative
RhoA. S1P also stimulated SMC growth by activating
the early growth response gene, c-fos. This effect was
not attenuated by Y-27632 but could be inhibited by the
MEK inhibitor, UO126. S1P enhanced SMC growth
through ERK-mediated phosphorylation of the SRF co-
factor, Elk-1, as measured by gel shift and Elk-1 acti-
vation assays. Taken together these results demon-
strate that S1P activates multiple signaling pathways
in SMC and regulates proliferation by ERK-dependent
activation of Elk-1 and differentiation by RhoA-de-
pendent activation of MRTF-A.
It is well established that SMC1 growth and differentiation
are regulated by a complex array of local environmental cues
including growth factors, contractile agonists, cell-cell and cell-
matrix interactions, inflammatory stimuli, and mechanical
stresses (see Refs. 1 and 2 for reviews). However, the cell
signaling mechanisms by which these stimuli regulate the ex-
pression of the SMC differentiation marker genes such as SM
-actin, SM22, and SM myosin heavy chain are not well un-
derstood. The transcription factor, serum response factor
(SRF), is clearly involved in regulating SMC-specific transcrip-
tion, (1–7) but SRF is also known to regulate growth response
genes such as c-fos, suggesting that signaling pathways exist
that differentially regulate SRF-dependent growth and SRF-
dependent differentiation (8, 9). Recent evidence indicates that
the myocardin family of SRF co-activators is important for
SMC differentiation and SRF-dependent gene regulation, but
the signaling mechanisms that regulate their function are vir-
tually unknown (10–14). We have shown that signaling
through the small GTPase, RhoA, regulates SMC-specific tran-
scription through SRF-dependent mechanisms, (15) and we
hypothesize that signaling through RhoA may integrate some
of the diverse signals that regulate SMC phenotype.
The lipid agonist, sphingosine 1-phosphate (S1P), has re-
cently been shown to have interesting effects on vascular de-
velopment and SMC growth and migration (see Refs. 18 and 19
for reviews). S1P is present in high concentrations in serum
and platelets and has been shown to affect a variety of impor-
tant vascular processes by binding specifically to the S1P sub-
family of the G-protein-coupled Edg receptors (16). S1P recep-
tors are found on SMC and endothelial cells (EC), and many
studies have shown that S1P can stimulate growth and migra-
tion in these and other cell types (17–22). S1P has been shown
to stimulate angiogenesis, enhance angiogenic responses to
basic fibroblast growth factor, and differentiate EC cultures
into endothelial tubes (23, 24). Interestingly, S1P induces ves-
sel maturation in many model systems by increasing EC adhe-
sive interactions and pericyte/SMC investment indicating that
it may be important for the full development of larger vessels
(25–27).
S1P-dependent signaling is fairly complex because of the
expression of multiple S1P receptor isoforms (S1P1 through
S1P5) that couple to several different G-proteins (see Refs. 18,
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32, and 33 for reviews). S1P receptors 1, 2, and 3 have been
studied in a variety of heterologous systems to identify recep-
tor-specific actions, and it is thought that the effects of S1P on
cell function are mainly determined by receptor subtype ex-
pression (28, 29). S1P1, which is highly expressed in EC, cou-
ples almost exclusively to Gi and stimulates cell growth
through activation of Ras/mitogen-activated protein kinase,
cell survival through AKT, and cell migration through activa-
tion of Rac1 (21, 22, 24, 30, 31). In contrast, S1P2, which is
expressed highly in adult medial SMC, couples only weakly to
Gi but strongly activates the small GTPase, RhoA, by coupling
to G12⁄13 (18, 32, 33). Activation of RhoA in SMC leads to in-
creased actin polymerization and cellular contractility and can
promote or inhibit SMC migration depending upon the model
system studied (34, 35). In HEK293 cells, overexpression of
S1P2 inhibited S1P- and insulin-like growth factor I-induced
migration by increasing RhoA activation and inhibiting Rac
(35). S1P3 can also activate RhoA under some conditions, and
both S1P2 and S1P3 have been shown to stimulate phospho-
lipase C by activating Gq (31, 36, 37). Some evidence suggests
that S1P may also act as an intracellular signaling molecule,
but little is known about its putative role as such (38).
The direct effects of S1P on SMC differentiation have not
been addressed, yet several lines of evidence suggest that
S1P signaling may be important for regulating this process.
First, the expression pattern and G-protein-coupling proper-
ties of S1P1 and S1P2 correlate very well with the growth and
migration properties of different SMC phenotypes. For exam-
ple, although adult medial SMC express little if any S1P1,
this growth-coupled receptor is expressed highly in medial
SMC during development and in intimal SMC (18). In fact,
overexpression of S1P1 in adult medial SMC can restore
growth responsiveness of SMC to S1P (18). In contrast, S1P2
is highly expressed in medial SMC, and stimulation of this
receptor inhibits SMC migration and stimulates SMC con-
traction (18, 39, 40). Second, S1P1 targeted mice die of hem-
orrhage at around embryonic day 13.5 because of lack of
vessel maturation with significant impairment of SMC in-
vestment of vessels (25). This SMC phenotype may be sec-
ondary to effects on EC (41), but S1P1 deletion may also have
cell autonomous effects on SMC during development. Finally,
S1P is a strong activator of RhoA in cells expressing S1P2 (33,
36). Because we have previously shown that SMC differenti-
ation marker gene expression is positively regulated by RhoA-
dependent activation of SRF (15), and medial SMC express
high levels of S1P2, we hypothesized that S1P stimulation
should enhance the differentiated SMC phenotype.
The goals of the current study were to determine the extent
to which S1P regulates SMC differentiation and to identify the
signaling mechanisms by which S1P stimulates changes in
gene expression in SMC. Results demonstrate that S1P in-
creases the expression of multiple SMC differentiation marker
genes by RhoA-mediated activation of SRF. Interestingly, these
effects may be mediated by the newly described SRF co-factor,
myocardin-related transcription factor A (MRTF-A). S1P also
moderately stimulated SMC proliferation, a process that was
dependent upon ERK and involved activation of another SRF
co-factor, Elk-1.
MATERIALS AND METHODS
Cell Culture, Transient Transfections, and Reporter Assays—SMCs
from rat thoracic aorta were isolated, cultured, and transfected as
described previously (42, 43). In short, cells were maintained in 24-well
plates in 10% serum and were transfected 24 h after plating at 70–80%
confluency using the transfection reagent Superfect (Qiagen) as per
protocol. The SM22 promoter (from 450 to 88), the SM -actin
promoter (from 2560 to 2784), the SM myosin heavy chain promoter
(from 4,200 to 11,600) and the c-fos promoter (from 356 to 109)
used in this study have been described previously (1, 4, 5, 44). The
CArG mutant SM -actin promoter has been described previously (45)
and was a generous gift from Gary Owens (University of Virginia). For
co-transfection experiments 100–250 ng of N19RhoA, MRTF-A, dom-
inant negative MRTF-A, or empty pcDNA vector was included with
promoter/reporter constructs. Prior to agonist treatment SMC were
placed in completely serum-free media for 48 h. 10T1⁄2 cells were
placed in 0.2% charcoal-treated serum (to remove active serum lip-
ids). Cells were treated with sphingosine 1-phosphate for 24 h, and
luciferase assays were performed using the Steady-Glo system (Pro-
mega). Sphingosine 1-phosphate used in these experiments was ob-
tained from Matreya and was maintained in 4 mg/ml fatty acid-free
bovine serum albumin, which was used as a vehicle control. In some
experiments cells were pre-treated with latrunculin B (0.5 M) for 10
min prior to the addition of S1P. Relative promoter activities are
expressed as the means  S.E. computed from a set of at least three
separate transfection experiments. We did not cotransfect a viral
promoter/Lac Z construct as a control for transfection efficiency be-
cause we have previously shown that such constructs exhibit un-
known and variable squelching effects on the SM-specific promoters,
presumably because of competition for common transcription factors
(46). Moreover, we have found that inclusion of such controls are
unnecessary in that variations in transfection efficiency between
independent experimental samples is routinely very small (10%)
(46).
RhoA and ERK Activity Assays—The pull-down assay used to meas-
ure RhoA activity has been previously described (47). In short, cell
lysates were rotated with 40 g of a GST-rhotekin Rho binding domain
fusion protein immobilized to glutathione-Sepharose 4B beads (Amer-
sham Biosciences) for 45 min at 4 °C in binding buffer (50 mM Tris, pH
7.6, 500 mM NaCl, 0.1% SDS, 0.5% deoxycholate, 1% Triton X-100, 0.5
mM MgCl2). Beads were washed three times (50 mM Tris, pH 7.6, 150
mM NaCl, 1% Triton X-100, 0.5 mM MgCl2) and resuspended in 2
Laemmli buffer. Proteins were separated on a 15% SDS-PAGE and
transferred to 0.2 m polyvinylidene difluoride (Bio-Rad). After
blocking in 3% bovine serum albumin/TBST (20 mM Tris-HCl, 500 mM
NaCl, 0.05% Tween-20, pH 7.4) for 2 h at room temperature, blots
were probed with 2 g/ml anti-RhoA (26C4) (Santa Cruz Biotechnol-
ogy) overnight at 4 °C. Loading controls (typically 10%) are taken
from each lysate sample prior to pull downs. For ERK assays, equal
amounts of S1P-treated and control cell lysates were run on a 10%
SDS-PAGE and transferred to nitrocellulose. ERK activity was then
measured using an activation-specific antibody (Cell Signaling). In
some experiments the MEK inhibitor UO126 was added 10 min prior
to S1P addition.
MRTF-A Western Blots and Constructs—Cell lysates were prepared
from rat aortic SMC, 10T1⁄2 cells, NIH3T3 fibroblasts, and A7r5 rat
fibroblasts. Seventy-five g of protein was separated on a 10% SDS-
PAGE, transferred to nitrocellulose, and probed for MRTF-A with a
polyclonal MRTF-A antibody that was a generous gift of Richard Tre-
isman (Cancer Research UK, London, UK). The Wt and N MRTF-A
constructs were a generous gift of Da-Zhi Wang (University of North
Carolina, Chapel Hill, NC). The dominant negative MRTF-A mutation
(lacking the trans-activation domain) was generated by sub-cloning
amino acids 1–631 into pcDNA3.1.
Quantitative PCR—RNA was prepared using the RNeasy kit with
RNase-free DNase (Qiagen) per the manufacturer’s instructions, and
RNA was quantified by Ribogreen Assay (Molecular Probes). One g
of RNA was used in a QPCR reaction containing 5 units of Reverse-iT
RTase blend (Abgene) and 2 Absolute QPCR mix (Abgene). For rat
myocardin amplification and detection, 0.05 g of forward (5-
CCAGCCCCCATCCTATGAA-3) and 0.05 g of reverse (5-GGAGT-
TCGTCCATCTGCTGA-3) primers and 0.7 M myocardin Taqman
probe (FAM-CCGAGTCATTTGCTGCTTCACTGCA-TAMRA) were
used in each reaction. MRTF-A was amplified and detected using 0.05
g of forward (5-CAACAGCCCTTGTCCCAG-3) and 0.05 g of re-
verse (5-GTTGCAAATGAAGGCTGAGGT-3) primers with 1.4 M
MRTF-A Taqman probe (FAM-CTGCCCAGATGGACCTGGAGCAC-
TAMRA). GAPDH was amplified and detected as a reference gene
using 0.025 g of forward (5-ATGGGTGTGAACCACGAGAA-3) and
0.025 g of reverse (5-GGCATGGACTGTGGTCATGA-3) primers
with 1 M GAPDH Taqman probe (TET-TGCATCCTGCACCAC-
CAACTGCTTAG-TAMRA). Each sample was done in triplicate; reac-
tions were analyzed using an ABI Prism 7700 sequence detector.
Cycling parameters were as follows: one cycle at 48 °C for 30 min, one
cycle at 95 °C for 10 min and 40 cycles (95 °C for 15 s, 60 °C for 1 min).
All expression data were normalized to expression of GAPDH.
Electrophoretic Mobility Shift and Elk-1 Activation Assays—Whole
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cell extracts were prepared by scraping SMC in lysis buffer (20 mM
HEPES, pH 7.9, 5 mM EDTA, 10 mM EGTA, 5 mM NaF, 0.1 g/ml
okadaic acid, 10% glycerol, 0.4 M KCl, 0.4% Triton X-100, 1 mM
dithiothreitol, 5 g/ml leupeptin, 5 g/ml aprotinin, 1 mM benzami-
dine). Lysates were left on ice for 5–10 min, and cell debris was
pelleted and discarded. Supernatants were then frozen in liquid N2
and stored at 80 °C for later use. Binding reactions were set up by
combining 25 g of lysate, a 32P-labeled oligonucleotide probe (20,000
cpm), and 0.25 g dIdC in binding buffer (10 mM Tris, pH 7.5, 50 mM
NaCl, 100 mM KCl, 1 mM dithiothreitol, 1 mM EDTA, 5% glycerol).
Reactions were incubated for 30 min before loading on non-
denaturing 5% polyacrylamide gel that was pre-run at 170V for 1 h.
Electrophoresis was performed at 170V in 0.5 TBE (45 mM Tris
borate, 1 mM EDTA). Gels were dried and exposed to film for 24–72
h at 80 °C. For supershift studies, 1 l of SRF or Elk-1 antibody
(both from Santa Cruz Biotechnology) was added after 20 min of
incubation. For measuring Elk-1 activation, S1P-treated and control
lysates were run on a 10% SDS-PAGE and transferred to nitrocellu-
lose. Phosphorylation of Elk-1 at Ser-383 was measured by probing
with a phosphospecific antibody (Cell Signaling).
FIG. 1. S1P stimulated SMC differentiation marker gene expression by activating RhoA. A, primary rat aortic SMC and 10T1⁄2 cells were
transfected with 0.75 g of SM22 promoter luciferase reporter construct. Cells were serum-starved for 48 h and then treated with S1P (1 M) for
24 h. In some experiments the Rho-kinase inhibitor, Y-27632 (10 M), or the MEK inhibitor, U-0126 (10uM), were added to cells 30 min prior to
S1P treatment. Promoter activities are expressed as -fold over vehicle treated set to 1  S.E. BSA, bovine serum albumin. B, rat aortic SMC and
10T1⁄2 cells were transfected with SM -actin and SM myosin heavy chain luciferase constructs, serum-starved, and treated with S1P as above.
SM22 results are included for comparison. C, SMC were serum-starved for 48 h and then treated with S1P for 48 h. Equal amounts of protein were
run on a 12% acrylamide gel and probed for SM -actin. D, wild type (Wt) and CArG mutant SM -actin promoters were transfected into 10T1⁄2 cells.
Cells were serum-starved for 48 h and then treated with S1P. E, SMC were serum-starved for 48 h and treated with S1P for the indicated time.
Cell lysates were incubated with GST-Rhotekin to pull down activated RhoA. Lysate controls (10%) and pull downs were run on an acrylamide gel
and probed with an Ab to RhoA.
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RESULTS
Medial SMC are known to express high levels of S1P2, a
G12⁄13-coupled receptor that signals through RhoA (18). Be-
cause we had shown previously that activation of RhoA stim-
ulates the expression of the SMC differentiation marker genes
(15), we hypothesized that S1P would increase SMC differen-
tiation marker gene expression. Results shown in Fig. 1 dem-
onstrate that S1P increased the expression of several SMC
differentiation marker genes in SMC by activating RhoA. S1P
stimulated a transiently transfected SM22-luciferase promoter
by more than 3-fold in primary SMC, and this effect was
blocked by treatment with the Rho-kinase inhibitor, Y-27632
but not by the MEK inhibitor UO126 (Fig. 1A). The multipotent
mouse embryonic 10T1⁄2 cell line has also been used to study
SMC-specific transcription because several SMC-specific mark-
ers can be up-regulated by stimulation with TGF- (48). S1P
stimulated the SM22 promoter in 10T1⁄2 cells by greater than
4-fold. Fig. 1B demonstrates that S1P also significantly up-
regulated the SM -actin and SM myosin heavy chain promot-
ers to a similar extent in both SMC and 10T1⁄2. Importantly, the
SM22 promoter, SM -actin promoter, and SM myosin heavy
chain promoters used in these studies were shown to direct
SMC-specific regulation of these genes in transgenic models (1,
3, 49) suggesting that S1P may be an important regulator of
SMC phenotype in vivo. S1P also stimulated the expression of
endogenous SM -actin as determined by Western blot analysis
(Fig. 1C). To determine whether the effects of S1P were medi-
ated by an SRF dependent mechanism, we transfected a SM
-actin promoter construct that contained mutations to the
CArG cis-element that mediate SRF binding. As shown in Fig.
1D, the CArG mutant construct was not activated by S1P. To
measure the effects of S1P on the activation of RhoA in SMC,
we used a GST-rhotekin fusion protein to precipitate GTP-
bound RhoA out of SMC lysates following treatment with S1P
(Fig. 1E). RhoA activation peaked between 2.5 and 5 min fol-
lowing S1P treatment and was sustained at substantial levels
at 15 min. Taken together, these results indicate that S1P
up-regulates SMC differentiation marker gene expression
through RhoA/Rho-kinase-dependent activation of SRF.
Several studies have shown that S1P can stimulate SMC
proliferation, but questions remain as to the specific S1P re-
ceptors involved and the precise signaling pathways that me-
diate this response. Data presented in Fig. 2A indicate that
S1P moderately stimulated SMC proliferation in a dose-de-
pendent fashion and that this effect was completely inhibited
by the MEK inhibitor, UO126. Fig. 2B demonstrates that S1P
activated ERK in a dose- and time-dependent manner and that
S1P-induced ERK activation was completely inhibited by
UO126. Fig. 2B also demonstrates that S1P is a relatively
strong activator of ERK in that concentrations of S1P as low as
100 nM activated ERK as efficaciously as 20 ng/ml platelet-
derived growth factor-. Importantly, SMC proliferation was
only slightly inhibited by Y-27632 indicating that if Rho-kinase
signaling is involved in the S1P-induced growth response it
plays only a minor role. S1P also stimulated the expression of
a transiently transfected c-fos promoter by 2.5-fold, an effect
not attenuated by Y-27632 (Fig. 2C). These data further sub-
stantiate that RhoA signaling (at least through Rho-kinase)
does not regulate S1P-induced cell proliferation in our cell
culture model.
The results presented so far indicate that S1P regulates
SMC differentiation through activation of RhoA and SMC
growth by activation of ERK signaling. Studies have shown
that one potential mechanism for agonist-induced effects on
SMC-specific transcription is increased SRF binding to the
SMC-specific promoters (50). To test this, we performed gel
shift analyses with an SRF-binding cis-element (CArG B) that
has been shown to be required for expression of SM -actin (1).
To test whether S1P affected SRF binding in a gene-specific
manner, we also included a shift probe for the c-fos SRE in
these experiments. Fig. 3A demonstrates that S1P treatment
did not increase SRF binding to the CArG B element. S1P also
had no effect on SRF binding to the c-fos SRE CArG element
(Fig. 3B, lower arrow) but did increase the presence of a higher
order complex by 2 h (Fig. 3B, small arrow). The higher order
complex was supershifted with an antibody to Elk-1 (Fig. 3B,
seventh lane) indicating that S1P treatment of SMC results in
FIG. 2. S1P stimulated SMC proliferation by activating ERK. A,
SMC were serum-starved for 48 h and then treated with S1P for 24 h.
In some experiments, Y-27632 or U-0126 were added just prior to S1P
treatment. Cell proliferation was measured indirectly by adding WST-1
tetrazolium salt (Roche Applied Science) per the manufacturer’s in-
structions. B, SMC were treated with the indicated concentration of
S1P or 20 ng/ml platelet-derived growth factor-. At 10 and 60 min
following treatment, cells were lysed and equal amounts of protein were
separated on SDS-PAGE. Blots were probed with a phospho-specific
antibody to ERK 1 and 2. The effects of U0126 on ERK activation are
shown in the bottom panel. C, SMC and 10T1⁄2 were transfected with
0.75 g of c-fos promoter luciferase reporter construct, serum-starved
for 48 h, and then treated with S1P  Y-27632. Promoter activities are
expressed as -fold over untreated set to 1.
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Elk-1 activation and ternary complex formation at the c-fos
SRE. S1P had no effect on SRF protein levels at any time point
based upon Western blot analysis (data not shown). To further
demonstrate that S1P induces Elk-1 activation, we used a
phospho-specific antibody to Elk-1 Ser-383 to probe control and
S1P-treated lysates. Fig. 3C demonstrates that S1P signifi-
cantly up-regulated Elk-1 phosphorylation by 2 h, a time course
of phosphorylation that closely paralleled the increase in
higher order complex formation observed in gel shifts. These
results indicate that S1P stimulates SMC growth by activating
early response gene expression through ERK-dependent acti-
vation of the SRF cofactor, Elk-1.
Our gel shift and SRF Western blot data indicated that
mechanisms unrelated to changes in SRF expression and DNA
binding are important for S1P-induced stimulation of SMC-
specific gene expression. It has recently been shown that the
myocardin family of SRF co-factors can dramatically up-regu-
late the expression of the SMC-specific genes and that myocar-
din-targeted mice fail to develop SMC (45, 51, 52). Myocardin is
expressed in rat aortic SMC, and reverse transcriptase-PCR
confirmed low but detectable levels of myocardin message in
our primary SMC cultures. Reverse transcriptase-PCR also
showed that SMC and 10T1⁄2 cells express significant levels
MRTF-A message, and Western analysis showed that SMC,
10T1⁄2, and A7r5 cells express substantial amounts of MRTF-A
protein (Fig. 4A). Therefore, S1P-induced up-regulation of ei-
ther myocardin or MRTF-A could explain the effects observed
in these experiments. To test this, we used quantitative reverse
transcriptase-PCR to measure the effects of S1P on myocardin
and MRTF-A mRNA levels. As shown in figure 4B, S1P slightly
decreased myocardin mRNA levels and had no effect on
MRTF-A indicating that other mechanisms must be responsi-
ble for the effects of S1P on SMC-specific transcription.
A recent study in NIH3T3 fibroblasts by Miralles et al. dem-
onstrated that MRTF-A activity was regulated by RhoA signal-
ing (12). This was a very important finding because it was the
first evidence to suggest that transactivation of SRF-dependent
genes by a myocardin family member could be achieved
through changes in cell signaling and not by increased tran-
scription factor expression. These authors demonstrated that
activation of RhoA caused MRTF-A to translocate from the
cytoplasm to the nucleus where it was then able to regulate a
variety of SRF-dependent structural genes.
To more directly test whether the effects of S1P on SMC
differentiation marker gene expression were dependent upon
MRTF-A, we co-transfected 10T1⁄2 cells with a C-terminal dele-
tion of MRTF-A that acts as a dominant negative. Previous
studies have shown that C-terminal deletions of the transacti-
vation domain of MRTF-A act as dominant negative mutations
(13). Results show that dominant negative MRTF-A attenuated
S1P-induced up-regulation of the SM22 promoter by nearly
80% (Fig. 5A). To provide additional support that the effects of
MRTF-A were mediated by RhoA signaling we co-transfected
cells with MRTF-A and a dominant negative N19RhoA. Fig. 5B
demonstrates that overexpression of MRTF-A resulted in a
200-fold increase in SM22 promoter activity and that expres-
sion of N19RhoA inhibited transactivation by MRTF-A in a
dose-dependent manner. To directly assess the effects of S1P on
MRTF-A localization, we expressed FLAG-tagged MRTF-A in
SMC, serum-starved the cells for 48 h, treated the cells with
S1P for 1 h, and then immunostained the cells using an anti-
FLAG antibody. Over 150 control and S1P-treated MRTF-A-
expressing cells were counted and scored in three separate
localization categories: nuclear, cytoplasmic, and diffuse. Rep-
resentative micrographs of each of these categories are shown
in Fig. 5C. In serum-starved cells MRTF-A localized to the
nucleus in 44% of the cells, to the cytoplasm in 37%, and as a
diffuse pattern in 19% (Fig. 5D). After 1 h of S1P treatment the
percentage of cells with nuclear staining increased to 88%,
whereas the fraction that showed cytoplasmic or diffuse stain-
ing decreased to 7 and 5%, respectively. Taken together these
data indicate that the effect of S1P on SMC-specific transcrip-
tion may be mediated by RhoA-dependent nuclear transloca-
tion of MRTF-A.
FIG. 3. S1P had no effect on SRF
binding to the SM -actin CArG B el-
ement but did activate Elk-1. A, dou-
ble-stranded CArG B probe was 32P-end-
labeled and annealed, purified on a 6%
acrylamide gel, eluted in TE (10 mM Tris,
pH 8.0, 1 mM EDTA), and precipitated
twice in ethanol. Electrophoretic mobility
shift assays were performed with 20 l of
cell lysate, 0.2–0.6 g of poly(dIdC) in 1
binding buffer (10 mM Tris-HCl, pH 7.5,
100 mM KCl, 50 mM NaCl, 1 mM dithio-
threitol, 1 mM EDTA, and 5% glycerol).
For supershifts, 1 l of SRF antibody
(Santa Cruz Biotechnology) was added af-
ter the 30-min incubation period, and the
reaction was incubated for an additional
15 min before loading. B, electromobility
shift assays were performed using an
SRE probe. Supershifts for Elk-1 were
performed with an Elk-1 antibody (Santa
Cruz Biotechnology). C, SMC were
treated with S1P for the indicated time.
Lysates were run on a 10% SDS-PAGE.
Blots were probed with a phospho-specific
Ab to Elk-1.
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The observation that S1P increased nuclear localization of
MRTF-A within 1 h of treatment suggests that the effects of
S1P on SMC-specific transcription should be relatively rapid
when compared with other pathways that require up-regula-
tion of a rate-limiting transcription factor. Therefore, we meas-
ured the activity of the SM -actin promoter at time points
shortly after S1P treatment. Results shown in figure 5E dem-
onstrate that SM -actin promoter activity was significantly
increased just 2 h after S1P treatment, reached a maximum by
3 h, and was sustained at 24 h. These results suggest that the
effects of S1P on SMC-specific transcription are caused by
signaling events that regulate the activity of transcription fac-
tors already present within the cell.
Previous studies have shown that MRTF-A nuclear translo-
cation is regulated at least in part by changes in actin polym-
erization and that the actin binding site in the N terminus of
MRTF-A is important for keeping MRTF-A in the cytoplasm
under unstimulated conditions (12). As shown in Fig. 6A, in-
hibiting actin polymerization with latrunculin B (LB) com-
pletely abolished the effects of S1P on SM22 promoter activity
in SMC and 10T1⁄2. Furthermore, whereas latrunculin B signif-
icantly inhibited transactivation of the SM22 promoter by full-
length MRTF-A, it had very little effect on transactivation by
an MRTF-A construct that lacked the N terminus (Fig. 6B).
These results strongly suggest that cytoplasmic localization of
MRTF-A is maintained by a mechanism that involves G-actin
binding to the N-terminal region of MRTF-A. They also support
a model in which S1P-dependent activation of SMC marker
gene expression by MRTF-A is mediated by RhoA-dependent
changes in actin polymerization.
DISCUSSION
A major goal of our laboratory has been to identify the
signaling mechanisms that control the transcription of the
SMC differentiation marker genes. The focus of the present
study was to determine whether S1P regulates SMC differen-
tiation and to identify the signaling mechanisms by which S1P
stimulates changes in gene expression in SMC. Because we had
previously shown that RhoA is an important regulator of SMC-
specific transcription, and S1P has been shown to stimulate
RhoA activation through S1P2-coupled activation of G12⁄13, we
hypothesized that S1P would up-regulate SMC differentiation
marker gene expression. The data presented indicate that: 1)
S1P stimulated expression of multiple SMC differentiation
markers in primary SMC cultures and in 10T1⁄2 cells in a
RhoA-dependent fashion. 2) S1P stimulated SMC proliferation
and c-fos expression. This effect was not dependent upon RhoA
but was dependent upon ERK activation of Elk1 and the for-
mation of the ternary complex at the c-fos SRE. 3) The effects
of S1P on SMC-specific transcription were mediated by RhoA-
dependent activation of the SRF co-factor, MRTF-A.
S1P signaling in the vasculature is certainly very complex.
Five separate S1P receptors have been identified that not only
differ in their patterns of expression but also in their coupling
to very different G-proteins. A number of studies have shown
that S1P regulates cell proliferation and migration, and the
current studies support a role for the involvement of S1P in
regulating SMC growth by stimulating ERK-dependent early
response gene expression. Importantly, we demonstrate for the
first time that S1P also stimulates SMC differentiation by
up-regulating the transcription of several SMC differentiation
marker genes. This effect did not require ERK activity but was
mediated by activation of RhoA. These data suggest that the
effects of S1P on SMC-specific transcription are mediated by
the S1P2 receptor that is expressed highly in differentiated
SMC and is coupled to G12⁄13, a well known activator of RhoA
signaling. The observation that S1P stimulated cell prolifera-
tion through activation of ERK but not RhoA suggests that the
growth and differentiation pathways stimulated by S1P di-
verge. The observations that S1P2 couples very weakly to Gi
and that S1P1 has been detected in adult SMC at very low
levels may explain the effects of S1P on ERK-dependent SMC
growth (18, 32). Alternatively, S1P has been shown to trans-
activate several receptor tyrosine kinases such as Flk-1 and
platelet-derived growth factor-, and a similar mechanism
could also be involved in these studies (48, 53).
The observation that S1P stimulates SMC growth and dif-
ferentiation provides evidence that these processes are not
necessarily mutually exclusive. RhoA and SRF are clearly in-
volved in regulating both of these important SMC functions,
and it will be critical to further clarify the specific signals that
differentiate these pathways. In our hands RhoA is more im-
portant for signaling SMC differentiation, whereas growth is
mainly regulated through ERK. However, RhoA activation has
also been shown to be required for growth factor-induced ex-
pression of c-fos, and recent evidence suggests that RhoA acti-
vation may be involved in the growth response of SMC to AII,
thrombin, and mechanical stretch (54–56). Taken together,
these results suggest that although basal RhoA activity is
required for SMC growth (perhaps through basal activation of
SRF), additional signaling pathways are probably more impor-
tant for regulating this process. In support of this idea, expres-
sion of constitutively active RhoA only potentiated SMC prolif-
eration in the presence of activated Ras, (56) and additional
FIG. 4. S1P did not increase myocardin or MRTF-A mRNA
levels. A, 75 g of protein from each of the indicated cell lysates was
separated on SDS-PAGE. Blots were probed with a polyclonal Ab to
MRTF-A. B, SMC were serum-starved for 48 h and then treated with
S1P for 24 h. RNA was prepared using the RNeasy kit with RNase-free
DNase (Qiagen) and quantified by Ribogreen assay (Molecular Probes)
per the manufacturer’s instructions. One g of RNA was used in a
quantitative PCR reaction containing primers and fluorescent Taqman
probes for myocardin or MRTF-A. GAPDH was used as a reference gene
in each PCR reaction, and all values were normalized to GAPDH mRNA
levels. mRNA was prepared from three separate experiments, and each
RNA sample was PCR tested in triplicate.
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signaling through the stress-activated protein kinase/c-Jun
NH2-terminal kinase pathway was required for Rho-mediated
regulation of c-fos (57).
The current findings are also very interesting in regard to
the observed vascular phenotypes of several targeted mouse
models in which genes in the S1P signaling pathway have been
deleted. Deletion of S1P1 in the mouse resulted in hemorrhagic
death at around embryonic day 13 because of incomplete in-
vestment of vessels with SMC and/or pericytes suggesting that
S1P is important for this process (25). Although SMC pheno-
type was not assessed rigorously in this model, at least some
SM -actin positive cells were associated with maturing vessels
in S1P1/ mice indicating that the S1P1 may regulate the
migration and proliferation of SMC as opposed to initial SMC
determination. Although it is impossible to completely rule out
a cell autonomous effect of S1P1 deletion on SMC differentia-
tion, we believe that the current studies indicate that it is
unlikely that signaling through S1P1 is essential for this proc-
ess. Interestingly, recent studies have shown that EC-specific
deletion of S1P1 resulted in a similar SMC phenotype to that
observed in S1P1-null mice suggesting that the effects of S1P1
deletion on SMC investment are mediated by EC-SMC inter-
actions (41).
Our data indicate that S1P activates the SMC differentiation
marker genes through activation of RhoA through S1P2 (or
perhaps S1P3), but it is currently unclear whether this signal-
ing pathway is required for differentiation of SMC in vivo. The
S1P2 and S1P3 receptors have been deleted individually in the
mouse resulting in fairly normal phenotypes (although seizures
were reported by one group) (36, 58, 59). Importantly, neither
of these deletions by themselves completely inhibited S1P-
induced RhoA activity indicating that both of these receptors
probably couple to G12⁄13 to activate RhoA (36). S1P2/S1P3
double knock-out mice did show perinatal lethality, and impor-
tantly embryonic fibroblasts isolated from these lines were not
able to activate RhoA in response to S1P (36). The precise cause
of death in the double knock-out mice is unclear, so it will be
important to analyze these mice for SMC phenotypes. It is
currently unknown whether signaling through S1P4 or S1P5
can compensate for loss of other receptors in this family and the
FIG. 5. The S1P-induced increase
in SM22 promoter activity was
dependent upon RhoA-induced nu-
clear translocation of MRTF-A. A,
10T1⁄2 cells were co-transfected with 0.75
g of SM22 luciferase and 0.25 g of dom-
inant negative MRTF-A. Cells were se-
rum-starved for 48 h then treated with
S1P for 24 h. B, 10T1⁄2 cells were trans-
fected with 0.75 g of SM22 luciferase, 0.1
g of MRTF-A (or empty vector), and in-
creasing amounts of dominant negative
N19RhoA. C, SMC were transfected with
FLAG-tagged MRTF-A. Cells were se-
rum-starved for 48 h and then treated for
1 h with S1P. Cells were fixed in 4%
paraformaldehyde, permeabilized, and
probed with an anti-FLAG antibody. Cells
were scored for MRTF-A localization in
three categories: nuclear, cytoplasmic, or
diffuse. D, 10T1⁄2 cells were transfected
with SM -actin/luciferase, serum-
starved for 48 h, treated with S1P for the
indicated times, and then assayed for
luciferase.
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role of these receptors in vascular maturation has not been well
studied. In addition, RhoA is known to be activated by a large
number of signaling pathways and Rho guanine exchange fac-
tors, and any one of these pathways may have compensated for
loss of RhoA activation in S1P2/S1P3 receptor targeted mice.
Interestingly, deletion of G13 also resulted in a vascular phe-
notype (60). As with the S1P1 deletion, the resulting lethality
was not caused by failure of endothelial cells to differentiate
but from failure to organize immature vessels into a function-
ing vascular network, a process that clearly involves intricate
signaling between EC and SMC.
The transcriptional mechanisms that regulate SMC-specific
protein expression and ultimately SMC differentiation are
starting to be defined. Extensive evidence indicates that most
(if not all) of the SMC-specific proteins are regulated by SRF.
The observation that CArG mutations in the SM -actin pro-
moter completely abolished the effects of S1P indicates that
SRF plays a role in the S1P-induced response. However, be-
cause SRF is expressed ubiquitously and also regulates cardiac
and skeletal muscle-specific genes and the early response
genes, additional mechanisms must be involved in SRF-de-
pendent cell type-specific gene regulation. The discovery of the
SRF co-factor, myocardin, by Wang et al. (51) was a very
important advance in this area. Myocardin was originally iden-
tified as a cardiac-specific gene but was also found to be highly
expressed in many SMC tissues during development (11). Myo-
cardin has been shown to strongly transactivate a number of
SRF-dependent muscle-specific promoters including the SMC
differentiation markers, SM -actin, SM22, and SM myosin
heavy chain (45, 52, 61). Importantly, myocardin targeted mice
show no apparent cardiac phenotype but die around embryonic
day 10.5 because of a lack of differentiated SMC indicating that
myocardin plays a critical role during early SMC differentia-
tion (61). We did detect low levels of myocardin message in our
SMC model by quantitative PCR, but S1P treatment failed to
increase myocardin expression. We cannot completely rule out
S1P-dependent regulation of the transcriptional activity of
myocardin by yet to be described changes in post-translational
modification.
Our data strongly suggest that the S1P-induced increase in
SMC differentiation marker gene expression was mediated by
another SRF co-factor in the myocardin family, MRTF-A. West-
ern blotting and reverse transcriptase-PCR demonstrated that
SMC and 10T1⁄2 cells express very high levels of MRTF-A, and
a dominant negative form of MRTF-A that lacked the C-termi-
nal trans-activation domain inhibited the effects of S1P on
SM22 promoter activity. Overexpression of MRTF-A in 10T1⁄2
cells also dramatically up-regulated SM -actin promoter ac-
tivity (200-fold). This effect was attenuated by co-expression
of a dominant negative form of RhoA indicating that S1P-de-
pendent activation of RhoA likely leads to increased MRTF-A-
dependent transcription. Others have also shown that MRTF-A
can strongly up-regulate a number of SRF-dependent muscle-
specific markers genes (11, 13, 14). Because MRTF-A is
thought to be more ubiquitously expressed than myocardin, its
precise involvement in regulating cell-type-specific SRF-
dependent transcription is less clear.
The observations that S1P had no effect on MRTF-A expres-
sion levels and that the effects of S1P on promoter activity were
maximal by 3 h indicate that signal-induced changes in the
transcriptional activity of MRTF-A may be involved. A recent
study in NIH 3T3 cells has demonstrated that MRTF-A activity
is regulated by RhoA-dependent changes in nuclear transloca-
tion (12). Our studies in SMC and 10T1⁄2 cells indicate that the
mechanisms that regulate MRTF-A nuclear localization may be
dependent upon cell type because a substantial number of
serum-starved cells contained MRTF-A in the nucleus (44%).
Nevertheless, S1P treatment caused a substantial rise in the
percentage of cells showing nuclear localization (to 88%), a
result that may explain the effects of S1P on SMC differentia-
tion marker gene expression. Our data also suggest that S1P
regulates MRTF-A localization through its effects on RhoA-de-
pendent actin polymerization and support the idea that
changes in actin dynamics are ultimately sensed by the actin
binding site contained in the N terminus of MRTF-A.
Interestingly, S1P has recently been shown to stimulate
SMC contraction by activating RhoA (39, 62, 63). Because
many of the SMC-specific differentiation marker genes code for
contractile or contractile-associated proteins, it is interesting to
postulate that short-term regulation of the SMC contractile
force by S1P (and possibly other agonists) may be coupled to
long-term regulation of SMC contractile-associated gene ex-
pression. In addition, many of the environmental factors that
control SMC phenotype including the contractile agonists, me-
chanical stretch, matrix interactions, and serum/growth factors
also affect RhoA activity, and signaling through this pathway
may be a common mechanism by which these factors contribute
to the regulation of SMC phenotype.
In summary, the data presented here indicate that S1P
regulates SMC differentiation through its effects on MRTF-A.
The control of MRTF-A localization by RhoA signaling in SMC
(and other cell types) may be an important link in the signaling
pathway by which SRF-dependent cell type-specific genes are
regulated by extrinsic factors. The observation that S1P also
regulates SMC growth by activating ERK suggests that sub-
FIG. 6. MRTF-A activity was regulated by actin dynamics. A,
10T1⁄2 cells were co-transfected with SM -actin/luciferase and MRTF-A.
Cells were serum-starved, pre-treated for 10 min with the actin depo-
lymerizing agent, latrunculin B (LB), and then treated with S1P. Lu-
ciferase activity was measured after 24 h, and all values are expressed
relative to non S1P-treated cells. B, 10T1⁄2 cells were co-transfected with
SM -actin/luciferase and either full-length MRTF-A or an MRTF-A
variant that lacked the N-terminal actin binding domain. Cells were
treated with LB and assayed for luciferase after 12 h.
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type-specific expression of S1P receptors may be an important
determinant of SMC phenotype. Because SMC differentiation
and changes in SMC phenotype are critical during blood vessel
development and cardiovascular pathophysiology, respectively,
further studies to identify the mechanisms by which S1P,
RhoA, and MRTF-A regulate these processes will be important.
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